ALKS
Alkermes plc
$49.55
▲ +1.14%
+$0.56
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
· price updated 9h ago
Alkermes plc
ALKS · NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · price updated 9h ago
$49.55
▲ +1.14% · +$0.56 today
AI research · $49.55
Track ALKS for continuous AI research
price position
Where ALKS sits now
52-week range
Low$25.17
High$55.67
Today $49.55
RSI (14)
24.9Oversold
03070100
fundamentals
Business quality and valuation
Operating record
What the business has actually produced
Revenue
Capital structure
Cash versus debt
Cash & investments$656.6M
Total debt$1.6B
Net cash after debt$-916.0M
Valuation
What the market charges
Forward P/E
Price against expected earnings
Needs attention · 433% above Sector avg
31.15x
Price / sales
Value assigned to each sales dollar
Reasonable · Between 3x and 8x sales
4.93x
Price / FCF
Price against free cash generation
Rich · Above 35x free cash flow
37.08x
EV / EBITDA
Operating value including debt
Rich · Above 22x EBITDA
51.06x
Quality
How efficiently it compounds
ROIC
Return earned on invested capital
Weak · Below 8% return on capital
5.5%
ROE
Profit generated from shareholder equity
Middle ground · Lagging most sector peers
3.9%
Debt / equity
Balance-sheet leverage
Middle ground · Roughly in line with sector
0.87x
Current ratio
Short-term assets against liabilities
Strong · Comfortable short-term liquidity
2.30x
Selected financial data sourced from StockAnalysis and refreshed weekly. Figures may be delayed and are for research context, not investment advice.
peer comparison
How ALKS compares
| company | mkt cap | P/E | rev growth | score |
|---|---|---|---|---|
| $8.22B | 127.3 | +10.8% | 37 |
 | $10.69B | 18.4 | +23.5% | 78 |
 | $4.88B | 20.3 | +10.3% | 77 |
 | $31.49B | 32.9 | +15.5% | 77 |
 | $1.08T | 41.4 | +47.4% | 76 |
US stock research
About Alkermes plc (ALKS) stock
Alkermes plc tracked in the US core universe. ALKS was +1.1% in the latest available session at $49.55. Its reported market value was $8.22B with a trailing P/E of 127.3. Latest reported revenue was $1.67B, changing +10.8% year over year, with $66.12M in net income.
Market snapshot updated Aug 3, 2026, 7:59 PM UTC.
- Latest available price
- $49.55
- Day change
- +1.1%
- Market cap
- $8.22B
- P/E (TTM)
- 127.3
- Revenue growth
- +10.8%
- Industry
- Drug Manufacturers - Specialty & Generic